Abbvie, Principia join forces on immunoproteasome inhibitors; Scripps develops heroin vaccine, FDA fast tracks NGF pain drug
→ Abbvie and Principia are collaborating to develop oral immunoproteasome inhibitors to treat autoimmune disease using novel technology discovered at Principia. Financial terms were not disclosed, but the two will work together during development and preclinical testing. Then Abbvie will move the technology forward to the clinical phase.
→ Scientists at the Scripps Research Institute have developed a vaccine against an unusual target – heroin. The researchers gave their vaccine to rhesus monkeys and showed that it prevented them from experiencing a high when exposed to the drug months later. The researchers will begin testing the vaccine, which they believe will help addicts avoid relapsing. The vaccine does not work for other opioids, nor does it prevent overdoses.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.